Massachusetts Financial Services Co. MA Sells 83,277 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Massachusetts Financial Services Co. MA lowered its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 10.2% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 729,830 shares of the company's stock after selling 83,277 shares during the period. Massachusetts Financial Services Co. MA owned 1.47% of Prestige Consumer Healthcare worth $52,621,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Intech Investment Management LLC bought a new stake in shares of Prestige Consumer Healthcare during the 3rd quarter worth approximately $620,000. Quest Partners LLC grew its holdings in Prestige Consumer Healthcare by 2,582.0% in the 3rd quarter. Quest Partners LLC now owns 11,774 shares of the company's stock valued at $849,000 after buying an additional 11,335 shares in the last quarter. Natixis Advisors LLC grew its holdings in shares of Prestige Consumer Healthcare by 11.4% during the 3rd quarter. Natixis Advisors LLC now owns 14,581 shares of the company's stock worth $1,051,000 after purchasing an additional 1,491 shares in the last quarter. Huntington National Bank grew its holdings in shares of Prestige Consumer Healthcare by 39.9% during the 3rd quarter. Huntington National Bank now owns 635 shares of the company's stock worth $46,000 after purchasing an additional 181 shares in the last quarter. Finally, MQS Management LLC acquired a new stake in shares of Prestige Consumer Healthcare during the 3rd quarter worth $552,000. Institutional investors own 99.95% of the company's stock.

Insider Activity

In other Prestige Consumer Healthcare news, insider William P'pool sold 8,987 shares of the firm's stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the sale, the insider now owns 20,058 shares of the company's stock, valued at approximately $1,641,747.30. This trade represents a 30.94 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Adel Mekhail sold 9,063 shares of the firm's stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total value of $743,166.00. Following the completion of the sale, the executive vice president now directly owns 18,365 shares of the company's stock, valued at $1,505,930. This trade represents a 33.04 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 38,810 shares of company stock valued at $3,187,300. Company insiders own 1.60% of the company's stock.

Prestige Consumer Healthcare Price Performance

Shares of PBH stock traded up $0.69 on Monday, hitting $85.54. 126,921 shares of the company's stock were exchanged, compared to its average volume of 251,165. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10. The stock has a market cap of $4.23 billion, a P/E ratio of 20.64, a price-to-earnings-growth ratio of 2.39 and a beta of 0.47. Prestige Consumer Healthcare Inc. has a 12 month low of $56.61 and a 12 month high of $86.36. The company has a 50 day moving average of $74.34 and a 200 day moving average of $70.69.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported $1.09 EPS for the quarter, meeting the consensus estimate of $1.09. The firm had revenue of $283.79 million during the quarter, compared to the consensus estimate of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The business's quarterly revenue was down .9% on a year-over-year basis. During the same period last year, the company earned $1.07 earnings per share. On average, equities research analysts predict that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on PBH. Jefferies Financial Group restated a "hold" rating and set a $76.00 price objective (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. DA Davidson restated a "buy" rating and set a $95.00 price objective on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. One analyst has rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, Prestige Consumer Healthcare has a consensus rating of "Moderate Buy" and an average price target of $83.67.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.